Health 18 September 2020 By Jessica Hamzelou Apps to track periods are more accurate when they include information on body temperature and other biomarkersRichard Drury/Getty Images Fertility-tracking apps can provide misleading information, and shouldn’t be relied upon to help conceive or as a contraceptive tool, according to an analysis of mobile phone apps available in…
Dr Carlos Chaccour had just woken up in Barcelona when he opened his laptop to read the latest Covid-19 research. Usually, he would start the day by meditating, but that was proving difficult in the middle of a global pandemic. Overnight, several colleagues had emailed him a large study that had just been published online which…
As disagreements pile up over easing COVID-19 restrictions and reopening businesses, scientists are racing to gauge how many people have truly been infected. Among other reasons, measuring the pandemic’s spread can clarify how deadly the disease is and how many people are presumably immune to it, which is crucial for anticipating future waves of the…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f